Working with complement without being defeated by it: why a complement c3 antibody has to be chosen against the fragment you actually want to detect rather than against the parent protein, how complement technology divides between activation assays, functional assays and detection reagents, what serum handling does to every complement measurement before an assay begins, and which controls make a complement result interpretable rather than merely reproducible
Complement is a cascade of proteolytic fragments, and almost every difficulty in measuring it comes from that fact. The protein you name is cleaved within minutes of a badly handled sample, the antibody you buy may recognise the parent, the fragment, the neoepitope or all three, and the result depends on which. This page is about choosing reagents that answer the intended question.
- protection of human subjects, 45 CFR
- Part 46
- the bloodborne pathogens standard, 29 CFR
- 1910.1030
- the biosafety manual that decides handling for human serum
- BMBL
The figures in this panel are regulation and manual identifiers, named from the documents themselves and linked below. They are not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a reagent price index it has not measured.
- 4 vendor service pages verifiedevery figure matched verbatim to the vendor's page
- Quoted and dated, never estimatedlast verification pass 2026-08-24
- 1 service classes coveredeach with measured search demand behind it
Designing complement work
- Name the fragment, not the protein. Detecting the intact component, a cleavage product or the neoepitope exposed by activation are three different measurements. Suppliers list them under the same protein name, so read the immunogen and the stated specificity rather than the product title.
- Fix sample collection before anything else. Complement activates ex vivo. The anticoagulant, the time to processing and the temperature all change the result, and a sample handled casually reports activation that happened in the tube. Standardise collection, process quickly, and aliquot to avoid freeze thaw.
- Separate functional from quantitative questions. A functional assay asks whether the pathway can proceed to completion; an immunoassay asks how much of a component is present. A deficiency shows in the first and may be invisible in the second, and the two are routinely confused when a result is interpreted.
- Choose the pathway you are interrogating. The classical, lectin and alternative routes converge but are initiated differently, and an assay that isolates one requires conditions that suppress the others. Using a general activation readout and inferring the pathway is a common error.
- Include activation and inhibition controls. A positive control that activates the cascade and a sample held under conditions that prevent activation bracket every run. Without them, a low result cannot be distinguished from a failed assay and a high one from a handling artefact.
The sample is the assay
No reagent choice compensates for a sample that activated before it reached the freezer. Because activation is fast and irreversible, the collection protocol is effectively part of the method, and it should be written, followed and recorded with the same care as the assay itself.
Where samples come from elsewhere, agree the handling in advance and ask for the timings. A sample of unknown provenance can be measured precisely and still mean nothing.
Reading a datasheet properly
For complement reagents the useful fields are the immunogen, the stated reactivity against parent and fragments, the applications validated, and whether the clone has been shown not to cross react with the neighbouring components of the cascade.
Where the datasheet is vague, ask the supplier directly and keep the answer with the reagent record. A clone whose specificity nobody can state is a clone whose results nobody can defend.
Common questions
- Why do complement results vary so much between laboratories?
- Sample handling, overwhelmingly. Time to processing, temperature and freeze thaw cycles change activation markers substantially, and these differences are rarely reported in enough detail to be reconciled.
- Does an antibody against a component detect its fragments?
- It depends entirely on the immunogen and the epitope. Some recognise the parent and every fragment containing that region; others are specific to a neoepitope that exists only after cleavage. The datasheet has to be read, not the product name.
- When is a functional assay necessary?
- Whenever the question is whether the pathway works, for example in suspected deficiency or when assessing an inhibitor. Component concentrations can look normal while function is absent, and only a functional readout distinguishes the two.
- How should serum samples be stored?
- Processed quickly, aliquoted in small volumes and held at low temperature, with the number of freeze thaw cycles recorded. Repeated thawing is the most common preventable cause of an uninterpretable complement result.
Get a shortlist for your project
Browse by service class
Sources
Cite or embed this figure
The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.
Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/complement-c3-antibody/.